spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  BARACLUDE 

 HSMN NewsFeed - 27 Mar 2018
Breckenridge Pharmaceutical, Inc. Announces Final Approval of its ANDA Entecavir tablets (Baraclude(R))
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 3 Jan 2018
Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jun 2017
Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 May 2011
Optimer Pharmaceuticals Expands Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Oct 2010
U.S. Food and Drug Administration Approves BARACLUDE(R) (entecavir) as a Treatment for Chronic Hepatitis B Patients with Evidence of Decompensated Liver Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Aug 2008
Bristol-Myers Squibb Welcomes NICE Guidance Recommending Baraclude(R) (entecavir) as a Treatment Option for Chronic Hepatitis B
Biopharmaceuticals
 HSMN NewsFeed - 24 Mar 2008
BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
Biopharmaceuticals
 HSMN NewsFeed - 2 Nov 2007
Ninety-one Percent of BARACLUDE(R) (entecavir) Treated Patients in a Four-Year Cohort Demonstrated Virologic Suppression to Undetectable Levels
Biopharmaceuticals
 HSMN NewsFeed - 21 May 2007
BARACLUDE(R) (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
Biopharmaceuticals
 HSMN NewsFeed - 14 Apr 2007
Four-Year Data Demonstrate Continued Low Incidence of BARACLUDE(R) (entecavir) Resistance in Nucleoside-naive Chronic Hepatitis B Patients
Biopharmaceuticals
 HSMN NewsFeed - 13 Apr 2007
BARACLUDE(R) (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment
Biopharmaceuticals
 HSMN NewsFeed - 14 Nov 2006
Bristol-Myers Squibb Company Announces Promotion of Andrew Bonfield and Elliott Sigal to Executive Vice Presidents
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Oct 2006
Three-Year Data Showed Low Incidence of BARACLUDE(R) (Entecavir) Resistance in Nucleoside-Naive Chronic Hepatitis B Patients
Biopharmaceuticals
 HSMN NewsFeed - 30 Oct 2006
BARACLUDE(R) (Entecavir) Demonstrated Viral Suppression to Undetectable Levels in Most Patients in a Three-Year Cohort
Biopharmaceuticals
 HSMN NewsFeed - 30 Oct 2006
Study Shows Treatment with BARACLUDE(R) (Entecavir) Resulted in Greater Viral Load Reductions Compared to Adefovir in Antiviral Naive Chronic Hepatitis B E-Antigen Positive Patients
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2006
96-Week Viral Suppression Data From Two Studies Presented for BARACLUDE(R) (entecavir) in Chronically-Infected Hepatitis B Patients
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 1 additional stories matching:
BARACLUDE
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.